BOT

14.3%

40.0¢ botanix pharmaceuticals ltd

Great post again mate.Be nice if this was further communicated...

First 863 Last

Share
Profile

Follow
bernsta

4,396 Posts.

1376

10/02/21

22:55

Post #: 50878002
Share

Originally posted by bigfella195: ↑

When the 1801 results were announced I was pleased that the primary endpoints had been achieved but was left with a few questions. I popped off an email to Botanix and this morning was able to get some answers. They could not have been any more open and forth coming, very appreciative. Thought I would share some insights:

- All 66 participants completed the trial. The participants were tested 3 times prior to the trial to determine if they had Staph Aureus. If they did not have a staph infection on the third test their data was not included and hence the percentages (A post yesterday clarified the calculations).

- There was no data collected at the end of day 5 as the trial was set up around the protocols of trials completed for other nasal decolonization products.

- 2 participants had MRSA, too few to be considered statistically significant. 1 in the vehicle group and 1 in the ointment group. The MRSA in the vehicle group was not eliminated, while the MRSA in the ointment group was successfully eliminated. Botanix had hoped there would be more MRSA cases.

- Side effects were really very mild, a little crustiness in some cases.

- The ASX no longer allow pharmaceutical companies to present comparisons with other company’s trials in announcements.

- The level of nasal staph was coded as eliminated, light, moderate or high. Data about staph levels in participants who were not classified as eliminated is still to come through.

- Participants who were recolognised by staph had there staph treated again and the staph was, in all cases, still susceptible suggesting no resistance development.

- In terms of recolognisation, staph is carried on many parts of the body and persistent carriers recolognize a lot. Other nasal decolonization studies gave participants full body chlorhexadine washes prior to the trial, something that was not done in Botanix’s trial.

- More data about the 1801 trial is still to come in.

-Matt Callaghan will be presenting remotely at a conference next week and hopefully will provide more data about the trial.

It is clear to me that Botanix genuinely believe the data is very good and compares well to competitors in the staph decolonization space, dialysis is one area they think this has some real potential.

My doubts about the results, based on some basic Google searches of other trials, were completely allayed. IMO Botanix is on to something and I’m not selling any time soon. Look forward to Matt’s presentation next week.

Expand

Great post again mate.

Be nice if this was further communicated in the announcements. Shareholder are left wanting more clarification. We are just battlers having a go.

BOT Price at posting: 15.0¢ Sentiment: Buy Disclosure: Held
13 Upvote

1 Great analysis

Reply

Top Stories

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

EBR

EBR reaches review milestone for wireless cardiac pacing device

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Results wrap: Austal, TPG Telecom and Downer

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

HLX

Helix investor makes partial takeover bid, proposing board changes

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

There are more pages in this discussion • 138 more messages in this thread...

First 863 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 40.0¢		Change 0.050(14.3%)		Mkt cap ! $724.0M

Open	High	Low	Value	Volume
35.5¢	40.0¢	35.5¢	$6.075M	15.87M

Buyers (Bids)

No.	Vol.	Price($)
5	287187	39.5¢

Sellers (Offers)

Price($)	Vol.	No.
40.0¢	1920397	33

View Market Depth

No.	Vol.	Price($)
5	287187	0.395
1	200000	0.385
8	750874	0.380
2	519612	0.375
5	213742	0.370

Price($)	Vol.	No.
0.400	1920397	33
0.405	180415	6
0.410	136081	11
0.415	100000	1
0.420	1137203	7

Last trade - 16.10pm 30/08/2024 (20 minute delay)

BOT (ASX) Chart

Great post again mate.Be nice if this was further communicated...

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

EBR reaches review milestone for wireless cardiac pacing device

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Results wrap: Austal, TPG Telecom and Downer

Lendlease sells off US east coast construction operations in latest global divestment push

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Helix investor makes partial takeover bid, proposing board changes

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great post again mate.Be nice if this was further communicated...

Top Stories

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

EBR reaches review milestone for wireless cardiac pacing device

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Results wrap: Austal, TPG Telecom and Downer

Lendlease sells off US east coast construction operations in latest global divestment push

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Helix investor makes partial takeover bid, proposing board changes

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News